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introduced in our legislation in 1979 (see more 
recently RD 1070/1999). However, it is debatable 
whether that generic consent to donate unless 
stated otherwise covers the consent to undergo 
the array of ante-mortem measures that precedes 
actual donation (basically preservation procedures). 
It is also doubtful that the protocol stated in the 
Real Decreto 1070/1999 is well-tuned to guarantee 
that the advanced directives of patients who suffer 
cardiac arrest outside the hospital are fully taken 
into account. On the other hand, to the extent that 
the ante-mortem measures are not administered 
for the benefit of the patient, it has been claimed 
that UDCCD is done in violation of Act 41/2002 
as well as the Convention of Human Rights and 
Biomedicine (the so called Oviedo Convention). 
CONCLUSIONS Our legal institutions, in Spain 
and elsewhere, currently foresee the possibility 
of undergoing medical procedures for the benefit 
of third parties (living organ donation is precisely 
the most poignant example), but it is much more 
doubtful that our praised opting-out scheme 
provides sufficient legal ground to UCDD as it is 
currently developed in Spain. 
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Objective: Ex vivo heart preservation has been 
proposed as a means to resuscitate donor hearts 
following cardiocirculatory death; however, the 
optimal method of oxygen delivery has not been 
established. Donor blood-based solutions contain 
immune cells that may propagate myocardial injury. 
We sought to determine if an acellular hemoglobin-
based oxygen carrier (Hemopure, OPK Biotech, 
USA) could provide equivalent preservation of 
myocardial function and energy metabolism. 
Methods: Twelve pig hearts were procured 
following cardioplegic arrest and perfused ex vivo 
at 37C. Group 1 hearts (G1, N=6) were perfused 
with a donor blood-STEEN solution ([Hb]=40g/L) 
and Group 2 hearts (G2, N=6) were perfused 
with a Hemopure-STEEN solution ([Hb]=40g/L). 
Hearts were transitioned into working mode for 
assessments at 1 (T1), 3 (T3), and 5 (T5) hours of 
ex vivo perfusion. Myocardial function and energy 
metabolism were assessed by pressure-volume loop 
analysis and 31P magnetic resonance spectroscopy, 
respectively. Results: G2 hearts demonstrated 
superior myocardial energy metabolism at 
T1 (inorganic phosphate/phosphocreatine: 
G2=0.29±0.04 vs. G1=0.49±0.03, p<0.01), 
although this was not observed at T3 (inorganic 
phosphate/phosphocreatine: G2=0.37±0.03 
vs. G1=0.44±0.02, p=0.12) or T5 (inorganic 
phosphate/phosphocreatine: G2=0.44±0.05 vs. 
G1=0.49±0.03, p=0.31). Diastolic function was 
comparable between groups at T1 (Tau: G2=62±6 
vs. G1=56±5, p=0.50); however, it was impaired in 
G2 hearts at T3 (Tau: G2=113±13 vs. G1=68±2, 
p<0.01) and T5 (Tau: G2=138±24 vs. G1=76±6, 
p=0.05). The development of myocardial edema 
in G2 hearts over the preservation interval (weight 
gain: G2=17±2 vs. G1=7±1 grams/hr, p<0.01) may 
account for these observations. Conclusions: Ex 
vivo perfusion with Hemopure may provide superior 
preservation of myocardial energy metabolism; 
however, methods to minimize myocardial edema 
are required to facilitate use as a donor blood 
alternative. 
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Background: Heart transplantation remains the 
only definite treatment option for end-stage heart 
diseases. The use of hearts procured after donation 
after circulatory death (DCD) could help decrease 
the heart graft shortage. The aim of this study was 
to evaluate the potential increase of heart graft 
pool by developing DCD heart transplantation. 
Methods: We retrospectively reviewed our local 
donor database from 2006- October 2012, and 
screened the complete controlled DCD donor 
population for potential heart donors, using the 
same criteria as for donation after brain death 
(DBD) heart transplantation. Acceptable donation 
warm ischemic time (DWIT) was limited to 30 min. 
Results: 206 DBD and 85 DCD were performed. 
From the 206 DBD, a total of 77 (37.4%) hearts 
were procured and transplanted. Out of the 85 
DCD, 10 (11.7%) donors fulfilled the criteria 
for heart procurement with a DWIT of under 30 
minutes. Within the same period, 90 patients were 
newly listed for heart transplantation, of which 59 
were transplanted, 22 died or were unlisted, and 9 
were waiting. Conclusions: It could be estimated 
that 10.5% of the DCD might be heart donors, 
representing a 16% increase in heart transplant 
activity, as well as potential reduction of the deaths 
on the waiting list by 45%. 
